Literature DB >> 22826396

Enhancement patterns of hepatocellular carcinoma after transarterial chemoembolization using drug-eluting beads on arterial phase CT images: a pilot retrospective study.

Woo-Suk Chung1, Kwang-Hun Lee, Mi-Suk Park, Yeo Jin Lee, Joonho Kwon, Song-Ee Baek, Myeong-Jin Kim.   

Abstract

OBJECTIVE: The purpose of this article is to assess CT enhancement patterns of hepatocellular carcinoma (HCC) within 1 month after transarterial chemoembolization (TACE) using drug-eluting beads and to determine whether enhancement patterns may be useful for predicting local tumor progression.
MATERIALS AND METHODS: Forty-one patients with 50 HCCs underwent CT within 1 month after TACE with drug-eluting beads. Two blinded readers independently reviewed the arterial phase images and classified enhancement patterns as follows: no enhancement, peripheral ring enhancement, and peripheral nodulelike enhancement. Enhancement patterns were correlated with time to tumor progression of enhancing tissue by log-rank test.
RESULTS: In the group with no enhancement, 92.3% (24/26) had not progressed and 7.7% (2/26) showed progression; for peripheral ring enhancement, 83.3% (10/12) had not progressed and 16.7% (2/12) showed progression; and for peripheral nodulelike enhancement, 16.7% (2/12) had not progressed and 83.3% (10/12) showed progression. The time to progression of enhancing tissue was significantly different between the group with no enhancement plus peripheral ring enhancement and the group with peripheral nodulelike enhancement (p < 0.001).
CONCLUSION: Analysis of enhancement patterns at the arterial phase of the first follow-up CT after TACE with drug-eluting beads is helpful for predicting progression of treated HCC.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22826396     DOI: 10.2214/AJR.11.7563

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  7 in total

Review 1.  Imaging appearance of treated hepatocellular carcinoma.

Authors:  Francesco Agnello; Giuseppe Salvaggio; Giuseppe Cabibbo; Marcello Maida; Roberto Lagalla; Massimo Midiri; Giuseppe Brancatelli
Journal:  World J Hepatol       Date:  2013-08-27

Review 2.  Locoregional therapies for hepatocellular carcinoma and the new LI-RADS treatment response algorithm.

Authors:  Ania Kielar; Kathryn J Fowler; Sara Lewis; Vahid Yaghmai; Frank H Miller; Hooman Yarmohammadi; Charles Kim; Victoria Chernyak; Takeshi Yokoo; Jeffrey Meyer; Isabel Newton; Richard K Do
Journal:  Abdom Radiol (NY)       Date:  2018-01

3.  Assessment of the response of hepatocellular carcinoma to interventional radiology treatments.

Authors:  Francesca Patella; Filippo Pesapane; Enrico Fumarola; Stefania Zannoni; Pietro Brambillasca; Ilaria Emili; Guido Costa; Victoria Anderson; Elliot B Levy; Gianpaolo Carrafiello; Bradford J Wood
Journal:  Future Oncol       Date:  2019-05-02       Impact factor: 3.404

4.  MRI Findings and Prediction of Time to Progression of Patients with Hepatocellular Carcinoma Treated with Drug-eluting Bead Transcatheter Arterial Chemoembolization.

Authors:  Seungsoo Lee; Kyung Ah Kim; Mi-Suk Park; Sun Young Choi
Journal:  J Korean Med Sci       Date:  2015-06-10       Impact factor: 2.153

5.  Transarterial chemoembolization with drug-eluting beads in hepatocellular carcinoma.

Authors:  Hee Chul Nam; Bohyun Jang; Myeong Jun Song
Journal:  World J Gastroenterol       Date:  2016-10-28       Impact factor: 5.742

6.  Rim Enhancement after Technically Successful Transarterial Chemoembolization in Hepatocellular Carcinoma: A Potential Mimic of Incomplete Embolization or Reactive Hyperemia?

Authors:  Kaspar Ekert; Christopher Kloth; Konstantin Nikolaou; Gerd Grözinger; Marius Horger; Wolfgang Thaiss
Journal:  Tomography       Date:  2022-04-15

7.  Does drug-eluting bead transcatheter arterial chemoembolization improve the management of patients with hepatocellular carcinoma? A meta-analysis.

Authors:  Shilong Han; Xiaoping Zhang; Liling Zou; Chenhui Lu; Jun Zhang; Jue Li; Maoquan Li
Journal:  PLoS One       Date:  2014-08-01       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.